AIMS/HYPOTHESIS: The aim of this study was to understand the role of CXC chemokine receptor 3 (CXCR3), a T-helper 1(Th1) type chemokine receptor, in the pathogenesis of type 1 diabetes. METHODS: We observed the incidence of diabetes in Cxcr3 homozygous knockout mice. We compared the expression pattern of various cytokines and chemokines and the frequency of FOXP3(+) cells in the pancreas and pancreatic lymph nodes from Cxcr3 ( -/- ) NOD mice and wild-type NOD mice. In addition, we observed the migration ability of CXCR3(+)CD4(+) cells to pancreatic islets upon adoptive transfer. Finally, we examined whether Cxcr3 (+) regulatory T cells (Tregs) actually suppressed the onset of diabetes in vivo. RESULTS: Cxcr3 ( -/- ) NOD mice developed spontaneous diabetes earlier than did wild-type NOD mice. In Cxcr3 ( -/- ) NOD mice, Tregs were more frequent in pancreatic lymph nodes and less frequent in pancreatic islets than in wild-type NOD mice. While transferred CXCR3(-)CD4(+) cells from wild-type NOD mice did not infiltrate pancreatic islets of NOD-severe combined immunodeficiency (SCID) mice, CXCR3(+)CD4(+) cells from the same mice migrated into the recipient islets and contained Forkhead box P3 (FOXP3) upon adoptive transfer. Moreover, CD4(+)CD25(+) cells from wild-type NOD mice suppressed and delayed the onset of diabetes compared with those from Cxcr3 ( -/- ) NOD mice in a cyclophosphamide-induced diabetes model system. CONCLUSIONS/ INTERPRETATION: The mechanism of accelerated diabetes onset in Cxcr3 ( -/- ) NOD mice was considered to be due to the lack of hybrid Tregs (CXCR3(+)FOXP3(+)CD4(+) cells), which could effectively migrate into and regulate Th1 inflammation in local lesions under Cxcr3 knockout conditions.
AIMS/HYPOTHESIS: The aim of this study was to understand the role of CXC chemokine receptor 3 (CXCR3), a T-helper 1(Th1) type chemokine receptor, in the pathogenesis of type 1 diabetes. METHODS: We observed the incidence of diabetes in Cxcr3 homozygous knockout mice. We compared the expression pattern of various cytokines and chemokines and the frequency of FOXP3(+) cells in the pancreas and pancreatic lymph nodes from Cxcr3 ( -/- ) NOD mice and wild-type NOD mice. In addition, we observed the migration ability of CXCR3(+)CD4(+) cells to pancreatic islets upon adoptive transfer. Finally, we examined whether Cxcr3 (+) regulatory T cells (Tregs) actually suppressed the onset of diabetes in vivo. RESULTS:Cxcr3 ( -/- ) NOD mice developed spontaneous diabetes earlier than did wild-type NOD mice. In Cxcr3 ( -/- ) NOD mice, Tregs were more frequent in pancreatic lymph nodes and less frequent in pancreatic islets than in wild-type NOD mice. While transferred CXCR3(-)CD4(+) cells from wild-type NOD mice did not infiltrate pancreatic islets of NOD-severe combined immunodeficiency (SCID) mice, CXCR3(+)CD4(+) cells from the same mice migrated into the recipient islets and contained Forkhead box P3 (FOXP3) upon adoptive transfer. Moreover, CD4(+)CD25(+) cells from wild-type NOD mice suppressed and delayed the onset of diabetes compared with those from Cxcr3 ( -/- ) NOD mice in a cyclophosphamide-induced diabetes model system. CONCLUSIONS/ INTERPRETATION: The mechanism of accelerated diabetes onset in Cxcr3 ( -/- ) NOD mice was considered to be due to the lack of hybrid Tregs (CXCR3(+)FOXP3(+)CD4(+) cells), which could effectively migrate into and regulate Th1inflammation in local lesions under Cxcr3 knockout conditions.
Authors: Marcus Müller; Sally L Carter; Markus J Hofer; Peter Manders; Daniel R Getts; Meghan T Getts; Angela Dreykluft; Bao Lu; Craig Gerard; Nicholas J C King; Iain L Campbell Journal: J Immunol Date: 2007-09-01 Impact factor: 5.422
Authors: Antje Rhode; Mary E Pauza; Ana Maria Barral; Evelyn Rodrigo; Michael B A Oldstone; Matthias G von Herrath; Urs Christen Journal: J Immunol Date: 2005-09-15 Impact factor: 5.422
Authors: Urs Christen; Dorian B McGavern; Andrew D Luster; Matthias G von Herrath; Michael B A Oldstone Journal: J Immunol Date: 2003-12-15 Impact factor: 5.422
Authors: A Hoerning; S Köhler; C Jun; B Tebbe; J Fu; J Menke; B Wilde; S Dolff; T Feldkamp; D M Briscoe; A Kribben; P F Hoyer; O Witzke Journal: Scand J Immunol Date: 2012-09 Impact factor: 3.487
Authors: Mara Kornete; Edward S Mason; Julien Girouard; Erin I Lafferty; Salman Qureshi; Ciriaco A Piccirillo Journal: PLoS One Date: 2015-05-06 Impact factor: 3.240
Authors: Ken T Coppieters; Natalie Amirian; Philippe P Pagni; Carmen Baca Jones; Anna Wiberg; Stanley Lasch; Edith Hintermann; Urs Christen; Matthias G von Herrath Journal: Diabetes Date: 2013-02-22 Impact factor: 9.461